The doses of paclitaxel and BKM120 were chosen from our previous reports (Genomic landscape of the PI3K-AKT pathway and the RAS-RAF-MEK-ERK pathway in ovarian cancer: A treatment strategy, Pradip De, et al., WIN 2016 June 27–28, Paris, France, Abstract # P4. This evidence concerns the gene MAP2K7 and ovarian cancer.